<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044066</url>
  </required_header>
  <id_info>
    <org_study_id>20172020</org_study_id>
    <nct_id>NCT04044066</nct_id>
  </id_info>
  <brief_title>Biomarker-based Prognostic Assessment</brief_title>
  <official_title>BIomarker-based Prognostic Assessment for Patients With Stable Angina and Acute Coronary Syndromes (BIPass)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital of Zibo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary artery disease (including stable angina and acute coronary disease) remains the
      leading mortality and morbidity worldwide. Improvement in biomarker, imaging research have
      led to new predictors for the prognosis, which may have great clinical value in the current
      era of personalized medicine. However, there is no available biomarker-based prediction rule
      for risk assessment of adverse events in patients with stable angina and acute coronary
      disease. Therefore, we aim to develop and validate a new biomarker-based risk model to
      improve the prognostication of adverse events (e.g. ischemic and bleeding events ) in the
      patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in Qilu Hospital of Shandong University (Jinan, China), Chinese PLA General
      Hospital Hospital (Beijing, China) and Peking University First Hospital (Beijing, China) are
      designed as the development cohort to derive the risk prediction models of ischemic and
      bleeding events. Patients enrolled in Peking University Third Hospital ( Beijing, China) Zibo
      Central hospital (Zibo, China) are designed as the independent validation cohort.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>12 months</time_frame>
    <description>a composite of cardiac death, myocardial infarction or stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>BARC 3 or more bleeding</description>
  </primary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Stable Angina</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma biomarker</intervention_name>
    <description>New emerging plasma biomarkers carrying prognositic information</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, whole blood, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In this prospective, multicenter registry study, we will consecutively enroll eligible
        patients according to the pre-specified inclusion and exclusion criteria in 6 tertiary
        hospitals in China. Patients meeting all eligibility criteria will be tracked and their
        hospitalization data will be collected including baseline clinical and demographic data,
        risk factors, blood drawn and storage, lab testing results, angiographic and procedural
        data (if appropriate), medication and adverse events. Clinical follow-up visits will be
        sheduled at 30 days, 6 months and 12 months after discharge by telephone contact. Follow-up
        data will be collected and assessment for death (cardiac, non-cardiac), myocardial
        infarction, stroke, revascularization or bleeding events will be conducted.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalized patients with the diagnosis of any type of coronary artery disease
             (stable angina, unstable angina, non ST-segment elevation myocardial infarction or
             ST-segment elevation myocardial infarction)

          2. Age â‰¥18 years of age and &lt;85 years of age

          3. Patient or guardian provided informed written consent

        Exclusion Criteria:

          1. Prior surgery (cardiac or non-cardiac), trauma or clinically evident coagulopathic
             bleeding (e.g. gastrointestinal, genitourinary, et al)

          2. Patient with non-cardiac co-morbidities with life expectancy less than 12 months

          3. Patients unwilling or unable to comply with all clinical follow-up schedules at 30
             days, 6 months and 12 months after discharge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuguo Chen, MD,PhD</last_name>
    <phone>+8618678812777</phone>
    <email>chen919085@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuguo Chen, MD,PhD</last_name>
      <phone>+8618678812777</phone>
      <email>chen919085@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

